Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.

Miyosawa K, Watanabe Y, Murakami K, Murakami T, Shibata H, Iwashita M, Yamazaki H, Yamazaki K, Ohgiya T, Shibuya K, Mizuno K, Tanabe S, Singh SA, Aikawa M.

Am J Physiol Endocrinol Metab. 2015 Jul 15;309(2):E177-90. doi: 10.1152/ajpendo.00528.2014. Epub 2015 May 26.

2.

Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists.

Matsuda T, Okuda A, Watanabe Y, Miura T, Ozawa H, Tosaka A, Yamazaki K, Yamaguchi Y, Kurobuchi S, Koura M, Shibuya K.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1274-8. doi: 10.1016/j.bmcl.2015.01.047. Epub 2015 Jan 28.

PMID:
25677664
3.

Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial.

Ishida T, Asano F, Yamazaki K, Shinagawa N, Oizumi S, Moriya H, Munakata M, Nishimura M; Virtual Navigation in Japan Trial Group.

Thorax. 2011 Dec;66(12):1072-7. doi: 10.1136/thx.2010.145490. Epub 2011 Jul 11.

4.

Clinical investigation of malignant mesothelioma in Japan.

Fujimoto N, Aoe K, Gemba K, Kato K, Yamazaki K, Kishimoto T.

J Cancer Res Clin Oncol. 2010 Nov;136(11):1755-9. doi: 10.1007/s00432-010-0834-7. Epub 2010 Mar 6.

PMID:
20213099
5.

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T.

Clin Cancer Res. 2009 Jul 1;15(13):4493-8. doi: 10.1158/1078-0432.CCR-09-0391. Epub 2009 Jun 16.

6.

Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy.

Oizumi S, Yamazaki K, Yokouchi H, Konishi J, Hommura F, Kojima T, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Int J Clin Oncol. 2009 Apr;14(2):125-9. doi: 10.1007/s10147-008-0808-9. Epub 2009 Apr 24.

PMID:
19390943
7.

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group.

J Clin Oncol. 2009 Mar 20;27(9):1394-400. doi: 10.1200/JCO.2008.18.7658. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 Jun 20;27(18):3071.

PMID:
19224850
8.

Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease.

Hasegawa N, Nishimura T, Watabnabe M, Tasaka S, Nakano Y, Yamazaki K, Hashimoto S, Nishimura M, Ishizaka A.

Pulm Pharmacol Ther. 2009 Jun;22(3):190-3. doi: 10.1016/j.pupt.2008.11.004. Epub 2008 Nov 21.

PMID:
19061965
9.

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T.

J Clin Oncol. 2008 Nov 20;26(33):5401-6. doi: 10.1200/JCO.2008.18.1974. Epub 2008 Oct 14.

PMID:
18854562
10.

Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.

Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, Oizumi S, Dosaka-Akita H, Nishimura M.

Cancer Immun. 2008 Aug 28;8:13.

11.

Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.

Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.

Jpn J Clin Oncol. 2008 May;38(5):339-46. doi: 10.1093/jjco/hyn024. Epub 2008 Apr 22.

PMID:
18434338
12.

Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells.

Oizumi S, Deyev V, Yamazaki K, Schreiber T, Strbo N, Rosenblatt J, Podack ER.

J Immunother. 2008 May;31(4):394-401. doi: 10.1097/CJI.0b013e31816bc74d.

PMID:
18391756
13.

Recurrent gefitinib-induced interstitial lung disease.

Suzuki M, Asahina H, Konishi J, Yamazaki K, Nishimura M.

Intern Med. 2008;47(6):533-6. Epub 2008 Mar 17.

14.

Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid.

Kikuchi E, Yamazaki K, Kikuchi J, Hasegawa N, Hashimoto S, Ishizaka A, Nishimura M.

Respirology. 2008 Mar;13(2):221-6. doi: 10.1111/j.1440-1843.2007.01208.x.

PMID:
18339019
15.

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC. Epub 2008 Mar 12.

PMID:
18337594
16.

Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.

Yokouchi H, Yamazaki K, Chamoto K, Kikuchi E, Shinagawa N, Oizumi S, Hommura F, Nishimura T, Nishimura M.

Cancer Sci. 2008 Feb;99(2):361-7. doi: 10.1111/j.1349-7006.2007.00664.x. Epub 2008 Jan 14.

17.

Diagnosis of peripheral pulmonary lesions using a bronchoscope insertion guidance system combined with endobronchial ultrasonography with a guide sheath.

Asano F, Matsuno Y, Tsuzuku A, Anzai M, Shinagawa N, Yamazaki K, Ishida T, Moriya H.

Lung Cancer. 2008 Jun;60(3):366-73. Epub 2007 Dec 4.

PMID:
18055063
18.

Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy.

Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, Hommura F, Oizumi S, Nishimura M, Shirato H.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):374-81. Epub 2007 Oct 29.

19.

Histopathologic consideration of fiducial gold markers inserted for real-time tumor-tracking radiotherapy against lung cancer.

Imura M, Yamazaki K, Kubota KC, Itoh T, Onimaru R, Cho Y, Hida Y, Kaga K, Onodera Y, Ogura S, Dosaka-Akita H, Shirato H, Nishimura M.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):382-4. Epub 2007 Sep 19.

PMID:
17881147
20.

Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma.

Yokouchi H, Chamoto K, Wakita D, Yamazaki K, Shirato H, Takeshima T, Dosaka-Akita H, Nishimura M, Yue Z, Kitamura H, Nishimura T.

Clin Exp Metastasis. 2007;24(7):533-40. Epub 2007 Jul 25.

PMID:
17653821

Supplemental Content

Loading ...
Support Center